GlassScriptPhysician profile
Marjorie M Schlecht
NPI 1649320334
$13,525.79
in general payments reported to CMS, 2019-2025
24 companies · $17.42 in 2025
The $17.42 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,051 · 2022: $3,357 · 2023: $4,362 · 2024: $2,738 · 2025: $17.42.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,116 · Education: $2.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,116.10 |
| Education | $2.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $2,224.35 | 2021-2024 | Austedo Xr, Uzedy, Austedo |
| Otsuka America Pharmaceutical, INC. | $1,305.48 | 2021-2024 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Vanda Pharmaceuticals INC. | $1,273.41 | 2021-2024 | Fanapt, Hetlioz |
| Janssen Pharmaceuticals, INC | $1,155.44 | 2021-2024 | Spravato, Invega Sustenna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,039.72 | 2021-2024 | Caplyta |
| Abbvie INC. | $991.45 | 2021-2024 | |
| Alkermes, INC. | $887.46 | 2021-2024 | Aristada, Lybalvi |
| Lundbeck LLC | $850.52 | 2021-2024 | Rexulti |
| Corium, LLC | $527.33 | 2022-2023 | Azstarys |
| Neurocrine Biosciences, INC. | $453.11 | 2021-2024 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $440.14 | 2021-2024 | Trintellix |
| Sunovion Pharmaceuticals INC. | $414.08 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $397.68 | 2023-2025 | Qelbree, Qelbree |
| Indivior INC. | $228.05 | 2021-2024 | Perseris |
| Ironshore Pharmaceuticals INC. | $218.85 | 2022-2024 | Jornay Pm |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $207.73 | 2022-2024 | Auvelity |
| Bausch Health US, LLC | $202.41 | 2023-2024 | Aplenzin, Wellbutrin |
| Almatica Pharma LLC | $180.83 | 2022-2024 | Loreev Xr, Sertraline Hcl |
| Merck Sharp & Dohme LLC | $150.61 | 2021-2023 | Belsomra |
| Noven Pharmaceuticals, INC. | $107.59 | 2024 | Xelstrym |
| Noven Therapeutics, LLC | $107.09 | 2023-2024 | Secuado, Xelstrym |
| Idorsia Pharmaceuticals US INC | $90.30 | 2022-2024 | Quviviq |
| Eisai INC. | $53.74 | 2021 | |
| Tris Pharma INC | $18.42 | 2023 | Dyanavel Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marjorie Schlecht listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.